1. Obach RS: Pharmacologically active drug metabolites: Impact on drug discovery and pharmacotherapy. Pharmacol Rev 65: 578‑640, 2013. 

2. Laizure SC, Herring V, Hu Z, Witbrodt K and Parker RB: The role of human carboxylesterases in drug metabolism: Have we overlooked their importance? Pharmacotherapy 33: 210‑222, 2013.

3. Gustavsson L: Pharmacogenomics in drug development. In: genomics and proteomics for clinical discovery and development. Springer, New York, NY, pp225‑241, 2014. 

4. Rowla nd A, M i ne r s JO a nd Ma cken z ie PI: T h e UDP‑glucuronosyltransferases: Their role in drug metabolism and detoxification. Int J Biochem Cell Biol 45: 1121‑1132, 2013.

5. Kaivosaari S, Finel M and Koskinen M: N‑glucuronidation of drugs and other xenobiotics by human and animal UDP‑glucuronosyltransferases. Xenobiotica 41: 652‑669, 2011.

6. Ishii Y, Nurrochmad A and Yamada H: Modulation of UDP‑glucuronosyltransferase activity by endogenous compounds. Drug Metab Pharmacokinet 25: 134‑148, 2010. 

7. Chang TKH: Drug‑metabolizing enzymes. In: Handbook of drug‑nutrient interactions. Boullata IJ and Armenti TV (eds). Humana Press, Totowa, NJ, pp85‑117, 2010. 

8. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS and Nebert DW: Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15: 677‑685, 2005. 

9. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, Oude Elferink RP, et al: The genetic basis of the reduced expression of bilirubin UDP‑glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 333: 1171‑1175, 1995.

10. Barbarino JM, Haidar CE, Klein TE and Altman RB: PharmGKB summary: Very important pharmacogene information for UGT1A1. Pharmacogenet Genomics 24: 177‑183, 2014.

11. Zhou Y, Wang SN, Li H, Zha W, Peng Q, Li S, Chen Y and Jin L: Quantitative trait analysis of polymorphisms in two bilirubin metabolism enzymes to physiologic bilirubin levels in Chinese newborns. J Pediatr 165: 1154‑1160.e1, 2014.

12. Bajro MH, Josifovski T, Panovski M, Jankulovski N, Nestorovska AK, Matevska N, Petrusevska N and Dimovski AJ: Promoter length polymorphism in UGT1A1 and the risk of sporadic colorectal cancer. Cancer Genet 205: 163‑167, 2012.

13. Monaghan G, Ryan M, Seddon R, Hume R and Burchell B: Genetic variation in bilirubin UPD‑glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 347: 578‑581, 1996.

14. Shatalova EG, Loginov VI, Braga EA, Kazubskaia TP,

Sudomoina MA, Blanchard RL and Favorova OO: Association

of polymorphisms in SULT1A1 and UGT1A1 Genes with breast cancer risk and phenotypes in Russian women. Mol Biol (Mosk) 40: 263‑270, 2006 (In Russian).

15. Chen YH, Hung SC and Tarng DC: Serum bilirubin links UGT1A1*28 polymorphism and predicts long‑term cardiovas cular events and mortality in chronic hemodialysis patients. Clin J Am Soc Nephrol 6: 567‑574, 2011. 16. Petersen JP, Ebbesen F, Hollegaard MV, Andersson S,

Hougaard DM, Thorlacius‑Ussing O and Henriksen TB: UGT1A1*28 genotypes and respiratory disease in very preterm

infants: A cohort study. Neonatology 109: 124‑129, 2016.

17. do Sameiro‑Faria M, Kohlova M, Ribeiro S, Rocha‑Pereira P, Teixeira L, Nascimento H, Reis F, Miranda V, Bronze‑da‑Rocha E, Quintanilha A, et al: Potential cardiovascular risk protection of bilirubin in end‑stage renal disease patients under hemodialysis. Biomed Res Int 2014: 175286, 2014.

18. Lodoso Torrecilla B, Palomo Atance E, Camarena Grande C, Díaz Fernández MC, Hierro Llanillo L, De la Vega Bueno A, Frauca Remacha E, Muñoz Bartolo G and Jara Vega P: Crigler‑Najjar syndrome: Diagnosis and treatment. An Pediatr (Barc) 65: 73‑78, 2006 (In Spanish).

19. Ciotti M, Chen F, Rubaltelli FF and Owens IS: Coding defect and a TATA box mutation at the bilirubin UDP‑glucuronosyltransferase gene cause Crigler‑Najjar type I disease. Biochim Biophys Acta 1407: 40‑50, 1998.

20. Petit FM, Hébert M, Gajdos V, Capel L, M'Rad R and Labrune P: Large deletion in UGT1A1 gene encompassing the promoter and the exon 1 responsible for Crigler‑Najjar type I syndrome. Haematologica 93: 1590‑1591, 2008.

21. Ko JS, Chang JY, Moon JS, Yang HR and Seo JK: Molecular analysis of the UGT1A1 gene in Korean patients with Crigler‑Najjar syndrome type II. Pediatr Gastroenterol Hepatol Nutr 17: 37‑40, 2014. 22. Chen K, Jin M, Zhu Y, Jiang Q, Yu W, Ma X and Yao K: Genetic polymorphisms of the uridine diphosphate glucuro nosyltransferase 1A7 and colorectal cancer risk in relation to

cigarette smoking and alcohol drinking in a Chinese population.

J Gastroenterol Hepatol 21: 1036‑1041, 2006.

23. Vogel A, Kneip S, Barut A, Ehmer U, Tukey RH, Manns MP and Strassburg CP: Genetic link of hepatocellular carcinoma with polymorphisms of the UDP‑glucuronosyltransferase UGT1A7 gene. Gastroenterology 121: 1136‑1144, 2001.

24. Zheng Z, Park JY, Guillemette C, Schantz SP and Lazarus P: Tobacco carcinogen‑detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk. J Natl Cancer Inst 93: 1411‑1418, 2001.

25. Strassburg CP, Vogel A, Kneip S, Tukey RH and Manns MP:

Polymorphisms of the human UDP‑glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer. Gut 50: 851‑856, 2002.

26. Vogel A, Ockenga J, Ehmer U, Barut A, Kramer FJ, Tukey RH, Manns MP and Strassburg CP: Polymorphisms of the carcin ogen detoxifying UDP‑glucuronosyltransferase UGT1A7 in proximal digestive tract cancer. Z Gastroenterol 40: 497‑502, 2002.

27. Huangfu H, Pan H, Wang B, Wen S, Han R and Li L: Association

between UGT1A1 polymorphism and risk of laryngeal squa mous cell carcinoma. Int J Environ Res Public Health 13: E112, 2016.

28. Maruo Y, Morioka Y, Fujito H, Nakahara S, Yanagi T, Matsui K, Mori A, Sato H, Tukey RH and Takeuchi Y: Bilirubin uridine diphosphate‑glucuronosyltransferase variation is a genetic basis of breast milk jaundice. J Pediatr 165: 36‑41.e1, 2014.

29. Yang H, Wang Q, Zheng L, Zheng XB, Lin M, Zhan XF and Yang LY: Clinical significance of UGT1A1 genetic analysis in chinese neonates with severe hyperbilirubinemia. Pediatr Neonatol 57: 310‑317, 2016. 

30. Azlin I, Wong FL, Ezham M, Hafiza A and Ainoon O: Prevalence of uridine glucuronosyl transferase 1A1 (UGT1A1) mutations in Malay neonates with severe jaundice. Malays J Pathol 33: 95‑100, 2011. 

31. Yu Z, Zhu K, Wang L, Liu Y and Sun J: Association of neonatal hyperbilirubinemia with UGT1A1 gene polymorphisms: A meta‑analysis. Med Sci Monit 21: 3104‑3114, 2015. 

32. Ando Y, Saka H, Asai G, Sugiura S, Shimokata K and Kamataki T: UGT1A1 genotypes and glucuronidation of SN‑38, the active metabolite of irinotecan. Ann Oncol 9: 845‑847, 1998. 

33. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL and Ratain MJ: Genetic predisposition to the metabolism of irinotecan (CPT‑11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN‑38) in human liver microsomes. J Clin Invest 101: 847‑854, 1998. 

34. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, et al: Genetic variants in the UDP‑glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22: 1382‑1388, 2004. 

35. Lankisch TO, Schulz C, Zwingers T, Erichsen TJ, Manns MP, Heinemann V and Strassburg CP: Gilbert's syndrome and irino tecan toxicity: Combination with UDP‑glucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol Biomarkers Prev 17: 695‑701, 2008. 

36. Jinno H, Tanaka‑Kagawa T, Hanioka N, Saeki M, Ishida S, Nishimura T, Ando M, Saito Y, Ozawa S and Sawada J: Glucuronidation of 7‑ethyl‑10‑hydroxycamptothecin (SN‑38), an active metabolite of irinotecan (CPT‑11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos 31: 108‑113, 2003. 

37. Wen F and Li Q: Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer. World J Gastroenterol 22: 5332‑5341, 2016. 

38. Xu C, Tang X, Qu Y, Keyoumu S, Zhou N and Tang Y: UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan‑based chemotherapy in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 78: 119‑130, 2016. 

39. Pacheco PR, Brilhante MJ, Ballart C, Sigalat F, Polena H, Cabral R, Branco CC and Mota‑Vieira L: UGT1A1, UGT1A6 and UGT1A7 genetic analysis: Repercussion for irinotecan pharmacogenetics in the Sao Miguel Island population (Azores, Portugal). Mol Diagn Ther 13: 261‑268, 2009. 

40. Rotger M, Taffe P, Bleiber G, Gunthard HF, Furrer H, Vernazza P, Drechsler H, Bernasconi E, Rickenbach M and Telenti A; Swiss HIV Cohort Study: Gilbert syndrome and the development of antiretroviral therapy‑associated hyperbilirubinemia. J Infect Dis 192: 1381‑1386, 2005. 

41. Lankisch TO, Moebius U, Wehmeier M, Behrens G, Manns MP, Schmidt RE and Strassburg CP: Gilbert's disease and atazanavir: From phenotype to UDP‑glucuronosyltransferase haplotype. Hepatology 44: 1324‑1332, 2006. 

42. Romero‑Lorca A, Novillo A, Gaibar M, Bandrés F and Fernández‑Santander A: Impacts of the glucuronidase genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on tamoxifen metabolism in breast cancer patients. PLoS One 10: e0132269, 2015.

43. Sutiman N, Lim JS, Muerdter TE, Singh O, Cheung YB, Ng RCH, Yap YS, Wong NS, Ang PCS, Dent R, et al: Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and their influence on tamoxifen disposition in asian breast cancer patients. Clin Pharmacokinet 55: 1239‑1250, 2016. 

44. Goey AK and Figg WD: UGT genotyping in belinostat dosing. Pharmacol Res 105: 22‑27, 2016. 

45. Goey AK, Sissung TM, Peer CJ, Trepel JB, Lee MJ, Tomita Y, Ehrlich S, Bryla C, Balasubramaniam S, Piekarz R, et al: Effects of UGT1A1 genotype on the pharmacokinetics, pharmacody namics, and toxicities of belinostat administered by 48‑hour continuous infusion in patients with cancer. J Clin Pharmacol 56: 461‑473, 2016. 46. Court MH, Freytsis M, Wang X, Peter I, Guillemette C,

Hazarika S, Duan SX, Greenblatt DJ and Lee WM; Acute Liver Failure Study Group: The UDP‑glucuronosyltransferase (UGT) 1A polymorphism c.2042C>G (rs8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A exon 5a/5b splice variant mRNA ratio, and

decreased risk of unintentional acetaminophen‑induced acute liver failure. J Pharmacol Exp Ther 345: 297‑307, 2013. 47. Kaplan M, Hammerman C and Maisels MJ: Bilirubin genetics

for the nongeneticist: Hereditary defects of neonatal bilirubin conjugation. Pediatrics 111: 886‑893, 2003.

48. Jancova P, Anzenbacher P and Anzenbacherova E: Phase II drug

metabolizing enzymes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 154: 103‑116, 2010.

49. Tourancheau A, Margaillan G, Rouleau M, Gilbert I, Villeneuve L, Lévesque E, Droit A and Guillemette C: Unravelling the transcriptomic landscape of the major phase II UDP‑glucuronosyltransferase drug metabolizing pathway using targeted RNA sequencing. Pharmacogenomics

J 16: 60‑70, 2016.

50. Girard H, Lévesque E, Bellemare J, Journault K, Caillier B

and Guillemette C: Genetic diversity at the UGT1 locus is

amplified by a novel 3' alternative splicing mechanism leading

to nine additional UGT1A proteins that act as regulators of glucuronidation activity. Pharmacogenet Genomics 17:

1077‑1089, 2007.

51. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS,

Church DM and Maglott DR: ClinVar: Public archive of relation ships among sequence variation and human phenotype. Nucleic Acids Res 42 (Database Issue): D980‑D985, 2014.

52. Beutler E, Gelbart T and Demina A: Racial variability in the

UDP‑glucuronosyltransferase 1 (UGT1A1) promoter: A balanced

polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 95: 8170‑8174, 1998.

53. Sai K and Saito Y: Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs. Expert Opin Drug Metab Toxicol 7: 967‑988, 2011.

54. Ca nu G, M i nucci A, Zuppi C a nd Capoluongo E:

Gilbert and Crigler Najjar syndromes: An update of the UDP‑glucuronosyltransferase 1A1 (UGT1A1) gene mutation database. Blood Cells Mol Dis 50: 273‑280, 2013.

55. Memon N, Weinberger BI, Hegyi T and Aleksunes LM: Inherited

disorders of bilirubin clearance. Pediatr Res 79: 378‑386, 2016.

56. Maisels MJ: Managing the jaundiced newborn: A persistent chal lenge. CMAJ 187: 335‑343, 2015.

57. Seco ML, del Río E, Barceló MJ, Remacha A, Ginovart G,

Moliner E and Baiget M: Interest in the study of genetic variants

of the promoter region of the UGT1A1 gene in neonatal jaundice. An Esp Pediatr 56: 139‑143, 2002 (In Spanish).

58. Ramos-Leví AM, Bernabeu I, Sampedro-Núñez M and Marazuela M: Genetic predictors of response to different medical therapies in acromegaly. Prog Mol Biol Transl Sci 138:

85-114, 2016.

59. Köhle C, Möhrle B, Münzel PA, Schwab M, Wernet D,

Badary OA and Bock KW: Frequent co‑occurrence of the TATA

box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP‑glucuronosyltransferase‑1

locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians. Biochem Pharmacol 65: 1521‑1527, 2003.

60. Bosma PJ: Inherited disorders of bilirubin metabolism.

J Hepatol 38: 107‑117, 2003.

61. Rodrigues C, Vieira E, Santos R, de Carvalho J, Santos‑Silva A, Costa E and Bronze‑da‑Rocha E: Impact of UGT1A1 gene variants on total bilirubin levels in Gilbert syndrome patients

and in healthy subjects. Blood Cells Mol Dis 48: 166‑172, 2012.

62. Ciotti M, Werlin SL and Owens IS: Delayed response to phenobarbital treatment of a Crigler‑Najjar type II patient

with partially inactivating missense mutations in the bilirubin UDP‑glucuronosyltransferase gene. J Pediatr Gastroenterol Nutr 28: 210‑213, 1999. 63. Maruo Y, Nakahara S, Yanagi T, Nomura A, Mimura Y, Matsui K, Sato H and Takeuchi Y: Genotype of UGT1A1 and phenotype correlation between Crigler‑Najjar syndrome type II and Gilbert syndrome. J Gastroenterol Hepatol 31: 403‑408, 2016.

64. Bosma PJ, Chowdhury NR, Goldhoorn BG, Hof ker MH, Oude Elferink RP, Jansen PL and Chowdhury JR: Sequence of exons and the flanking regions of human bilirubin‑UDP‑

glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler‑Najjar syndrome, type I. Hepatology 15: 941‑947, 1992.

65. Bosma PJ, Goldhoorn B, Oude Elferink RP, Sinaasappel M, Oostra BA and Jansen PL: A mutation in bilirubin uridine 5'‑diphosphate‑glucuronosyltransferase isoform 1 causing Crigler‑Najjar syndrome type II. Gastroenterology 105: 216‑220, 1993. 

66. Petit F, Gajdos V, Capel L, Parisot F, Myara A, Francoual J and Labrune P: Crigler‑Najjar type II syndrome may result from several types and combinations of mutations in the UGT1A1 gene. Clin Genet 69: 525‑527, 2006. 

67. Servedio V, d'Apolito M, Maiorano N, Minuti B, Torricelli F, Ronchi F, Zancan L, Perrotta S, Vajro P, Boschetto L and Iolascon A: Spectrum of UGT1A1 mutations in Crigler‑Najjar (CN) syndrome patients: Identification of twelve novel alleles and genotype‑pheno type correlation. Hum Mutat 25: 325, 2005. 

68. Fa ng J L a nd L a za r us P: Cor relat ion b et we en t he U DP‑glucuronosyltransferase (UGT1A1) TATA A box polymorphism and carcinogen detoxification phenotype: significantly decreased glucuronidating activity against benzo(a) pyrene‑7,8‑dihydrodiol(‑) in liver microsomes from subjects with the UGT1A1*28 variant. Cancer Epidemiol Biomarkers Prev 13: 102‑109, 2004. 

69. Thibaudeau J, Lépine J, Tojcic J, Duguay Y, Pelletier G, Plante M, Brisson J, Têtu B, Jacob S, Perusse L, et al: Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4‑hydroxylated metabolites of estradiol and estrone. Cancer Res 66: 125‑133, 2006. 

70. Guillemette C, Bélanger A and Lépine J: Metabolic inactivation of estrogens in breast tissue by UDP‑glucuronosyltransferase enzymes: An overview. Breast Cancer Res 6: 246‑254, 2004.

71. Eskandari‑Nasab E, Hashemi M, Rezaei H, Fazaeli A, Mashhadi MA, Moghaddam SS, Arbabi F, Jahantigh M and Taheri M: Evaluation of UDP‑glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer. Mol Biol Rep 39: 10531‑10539, 2012. 

72. McCarty MF: ‘Iatrogenic Gilbert syndrome'‑a strategy for reducing vascular and cancer risk by increasing plasma unconju gated bilirubin. Med Hypotheses 69: 974‑994, 2007. 

73. Wallner M, Marculescu R, Doberer D, Wolzt M, Wagner O, Vitek L, Bulmer AC and Wagner KH: Protection from age‑related increase in lipid biomarkers and inflammation contributes to cardiovascular protection in Gilbert's syndrome. Clin Sci (Lond) 125: 257‑264, 2013. 

74. Zucker SD, Horn PS and Sherman KE: Serum bilirubin levels in the U.S. population: Gender effect and inverse correlation with colorectal cancer. Hepatology 40: 827‑835, 2004. 

75. Glimelius B, Garmo H, Berglund A, Fredriksson LA, Berglund M, Kohnke H, Byström P, Sørbye H and Wadelius M: Prediction of irinotecan and 5‑fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J 11: 61‑71, 2011. 

76. Ushijima K, Kamura T, Tamura K, Kuzuya K, Sugiyama T, Noda K and Ochiai K: Docetaxel/irinotecan combination chemo therapy in platinum/taxane‑refractory and ‑resistant ovarian cancer: JGOG/WJGOG intergroup study. Int J Clin Oncol 18: 126‑131, 2013. 

77. Osawa K: Gene polymorphisms and chemotherapy in non‑small cell lung cancer. Zhongguo Fei Ai Za Zhi 12: 837‑840, 2009.

78. Yang C, Liu Y, Xi WQ, Zhou CF, Jiang JL, Ma T, Ye ZB, Zhang J and Zhu ZG: Relationship between UGT1A1*6/*28 polymor phisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan‑containing regi mens. Drug Des Devel Ther 9: 3677‑3683, 2015. 

79. Phelip JM, Mineur L, De la Fouchardière C, Chatelut E, Quesada JL, Roblin X, Pezet D, Mendoza C, Buc E and Rivoire M: High resectability rate of initially unresectable colorectal liver metastases after UGT1A1‑adapted high‑dose irinotecan combined with LV5FU2 and cetuximab: A multicenter phase II study (ERBIFORT). Ann Surg Oncol 23: 2161‑2166, 2016. 

80. Chiorean EG, Sanghani S, Schiel MA, Yu M, Burns M, Tong Y, Hinkle DT, Coleman N, Robb B, LeBlanc J, et al: Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine‑based chemoradiotherapy for locally advanced rectal cancer: Hoosier oncology group GI03‑53. Cancer Chemother Pharmacol 70: 25‑32, 2012.

81. Whirl‑Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thor n CF, Altman R B and Klein TE: Pharmacogenomics knowledge for personalized medicine. Clin

Pharmacol Ther 92: 414‑417, 2012.

82. Lowenberg D, Thorn CF, Whirl-Carrillo M, Ramirez J, Gong L,

Marsh S, Schuetz EG, Dolan ME, Innocenti F, McLeod HL

and Ratain MJ: Irinotecan Pathway, Pharmacokinetics: Pharmacogenomics Knowledge Base (PharmGKB) and Stanford University. https://www.pharmgkb.org/pathway/PA2001.

Accessed December 19, 2016.

83. Marsh S and Hoskins JM: Irinotecan pharmacogenomics.

Pharmacogenomics 11: 1003‑1010, 2010.

84. Satoh T, Ura T, Yamada Y, Yamazaki K, Tsujinaka T, Munakata M, Nishina T, Okamura S, Esaki T, Sasak Y, et al:

Genotype‑directed, dose‑finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci 102: 1868‑1873, 2011. 85. Atasilp C, Chansriwong P, Sirachainan E, Reungwetwattana T,

Chamnanphon M, Puangpetch A, Wongwaisayawan S and

Sukasem C: Correlation of UGT1A1(*)28 and (*)6 polymor phisms with irinotecan‑induced neutropenia in Thai colorectal

cancer patients. Drug Metab Pharmacokinet 31: 90‑94, 2016. 86. Pichereau S, Le Louarn A, Lecomte T, Blasco H, Le Guellec C and Bourgoin H: Cost‑Effectiveness of UGT1A1*28 genotyping

in preventing severe neutropenia following FOLFIRI therapy in

colorectal cancer. J Pharm Pharm Sci 13: 615‑625, 2010.

87. Paulík A, Grim J and Filip S: Predictors of irinotecan toxicity

and efficacy in treatment of metastatic colorectal cancer. Acta

Medica (Hradec Kralove) 55: 153‑159, 2012.

88. Banerjee SS, Aher N, Patil R and Khandare J: Poly(ethylene glycol)‑prodrug conjugates: Concept, design, and applications. J Drug Deliv 2012: 103973, 2012.

89. Giustina A, Ambrosio MR, Beck Peccoz P, Bogazzi F, Cannavo' S,

De Marinis L, De Menis E, Grottoli S and Pivonello R: Use of

Pegvisomant in acromegaly. An Italian society of endocrinology guideline. J Endocrinol Invest 37: 1017‑1030, 2014.

90. Buchfelder M, Schlaffer S, Droste M, Mann K, Saller B,

Brübach K, Stalla GK and Strasburger CJ; GermanPegvisomant Observational Study: The German ACROSTUDY: Past and present. Eur J Endocrinol 161 (Suppl 1): S3‑S10, 2009. 91. Mallea‑Gil MS, Bernabeu I, Spiraquis A, Avangina A, Loidi L and Ballarino C: Pegvisomant‑induced cholestatic hepatitis in

an acromegalic patient with UGT1A1 () 28 mutation. Case Rep Endocrinol 2016: 2087102, 2016.

92. Bernabeu I, Marazuela M, Lucas T, Loidi L, Alvarez‑Escolá C,

Luque‑Ramírez M, Fernandez‑Rodriguez E, Paniagua AE, Quinteiro C and Casanueva FF: Pegvisomant‑induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert's syndrome. J Clin Endocrinol Metab 95: 2147‑2154, 2010. 93. Filopanti M, Barbieri AM, Mantovani G, Corbetta S, Gasco V,

Ragonese M, Martini C, Bogazzi F, Colao A, Ferone D, et al: Role of UGT1A1 and ADH gene polymorphisms in pegvi somant‑induced liver toxicity in acromegalic patients. Eur J

Endocrinol 170: 247‑254, 2014.

94. Bernabeu I, Cameselle‑Teijeiro J, Casanueva FF and Marazuela M: Pegvisomant‑induced cholestatic hepatitis with jaundice in a patient with Gilbert's syndrome. Eur J Endocrinol 160: 869‑872, 2009.

95. Park WB, Choe PG, Song KH, Jeon JH, Park SW, Kim HB,

Kim NJ, Oh MD and Choe KW: Genetic factors influencing severe atazanavir‑associated hyperbilirubinemia in a population

with low UDP‑glucuronosyltransferase 1A1*28 allele frequency.

Clin Infect Dis 51: 101‑106, 2010.

96. Choe PG, Pa rk W B, Song JS, K im N H, Song K H, Park SW, Kim HB, Kim NJ and Oh MD: Incidence of

atazanavir‑associated hyperbilirubinemia in Korean HIV

patients: 30 months follow‑up results in a population with low

UDP‑glucuronosyltransferase1A1*28 allele frequency. J Korean

Med Sci 25: 1427‑1430, 2010.

97. S a n c h e z ‑ D o m i n g u e z C N , G a l l a r d o ‑ B l a n c o H L , Ro d r ig uez‑ Ro d r ig uez A A, Vela ‑ G on z a lez AV a nd

Sanchez‑Dominguez M: Nanoparticles vs. cancer: A multifun cional tool. Curr Top Med Chem 14: 664‑675, 2014.